Biology:Gp100:209-217(210M)

From HandWiki
Short description: Peptide cancer vaccine

Gp100:209-217(210M) is a synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a methionine substitution at position 210.[1] It is often referred to as the gp100 cancer vaccine which can also include other peptides based on gp100 (for example gp100:280-288(288V)).[2][3]

Clinical trials

It gave good results in a trial for advanced melanoma when used in combination with interleukin-2.[4] Another trial against Ipilimumab in advanced melanoma suggested Ipilimumab may be better than the gp100 vaccine alone.[5]

References

  1. ↑ NCI Drug Dictionary cancer.gov
  2. ↑ NCI Drug Dictionary cancer.gov
  3. ↑ "Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma". 2010. http://abstract.asco.org/AbstView_74_47740.html. 
  4. ↑ "Vaccine shows promise in advanced melanoma -study". Reuters. 30 May 2009. https://www.reuters.com/article/idUSN2934064820090530. 
  5. ↑ "BMS' Ipilimumab Proves Itself in Metastatic Melanoma Patients". 7 June 2010. http://www.genengnews.com/gen-news-highlights/bms-ipilimumab-proves-itself-in-metastatic-melanoma-patients/81243496/. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Gp100:209-217(210M)&oldid=3633366"